- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01213732
Phase 1 Dose-finding Study of L19TNFα Plus Melphalan Using Isolated Inferior Limb Perfusion (ILP) in Subjects With Intransit Stage III/IV Melanoma
Phase 1 Dose-finding Study of Tumor-targeting Human Monoclonal Antibody-cytokine Fusion Protein L19TNFα Plus Melphalan Using Isolated Inferior Limb Perfusion in Patients With In-transit Stage III/IV Melanoma.
In this study the recombinant human fusion protein L19TNFα will be associated in ILP with the standard treatment with melphalan 10mg/l limb volume in subjects affected by stage III/IV limb melanoma.
The recombinant human fusion protein L19TNFα was created with the intention to target TNFα directly to tumor tissues with the result in high and sustained intralesional bioactive TNFα concentrations.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Genova, Italy
- Azienda Ospedaliera Universitaria San Martino
-
Milano, Italy
- Fondazione IRCCS Istituto Nazionale dei Tumori
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subjects aged >18 years.
- Histologically or cytologically confirmed intransit stage III/IV melanoma of lower extremity distal to the apex of the femoral triangle
- ECOG performance status ≤ 2.
- Subjects must have at least one unidimensional clinically measurable lesion as defined by RECIST criteria (see Section 8). This lesion must not have been irradiated within four weeks during previous treatments.
- Absolute neutrophil count (ANC) ≥ 1.5 x 109/L, platelets ≥ 100 x 109/L, and haemoglobin (Hb) ≥ 9.5 g/dl.
- All acute adverse effects (excluding alopecia) of any prior therapy (including surgery, radiation therapy, chemotherapy) must have been resolved to ≤ Grade 1, except elevated liver transaminases judged to be associated with tumor infiltration (see below) (graded according to National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events, version 3.0 [CTCAE, v.3.0].
- Alkaline phosphatase (AP), alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) ≤ 2.5 x upper limit of normal (ULN), and total bilirubin ≤ 2.0 mg/dL unless liver involvement by the tumor, in which case the transaminase levels up to 5 x ULN are allowed.
- Creatinine ≤ 1.5 ULN or 24 h creatinine clearance ≥ 60 mL/min.
- Testing negative for acute or chronic infection with hepatitis B or C virus, or human immunodeficiency virus 1 or 2.
- Negative pregnancy test for females of childbearing potential at the screening visit.
- Commitment from subject to practice medically appropriate/acceptable method of birth control (e.g., hormonal, condoms or other adequate barrier controls, intrauterine contraceptive device, or sterilization) beginning at the screening visit and continuing until 3 months following the treatment with study drug
- Able to provide written Informed Consent
- Willingness and ability to comply with the scheduled visits, treatment plan, laboratory tests and other study procedures.
Exclusion Criteria:
- Breastfeeding women
- Presence of active infections (e.g. requiring antimicrobial therapy) or other severe concurrent disease, which, in the opinion of the Investigator, would place the subject at undue risk or interfere with the study.
- Active autoimmune disease.
Cardiac disease as manifested by any of the following:
- > Grade II heart failure, graded per New York Heart Association (NYHA) criteria.
- Unstable angina pectoris
- Acute or subacute coronary syndromes, including myocardial infarction, occurring with 1 year prior to study treatment
- Arrhythmia needing continuous treatment
- Ejection fraction less than the institutional lower limit of normal as assessed by multigated radionuclide angiography (MUGA) scan or echocardiogram
- Uncontrolled hypertension.
- History of claudication or Ischemic peripheral vascular disease (Grade IIb-IV).
- Chronic obstructive pulmonary disease or other chronic pulmonary disease with PFTs less than 50% predicted for age.
- Symptomatic cerebrovascular disease.
- Active peptic ulcer disease.
- Concurrent infection of HIV.
- Severe diabetic retinopathy.
- Major surgery or trauma within 4 weeks prior to start of study treatment.
- Hypersensitivity to melphalan or TNFα or other intravenously administered human proteins/peptides/antibodies.
- Chemotherapy, radiation therapy or therapy with an investigational agent within 4 weeks prior to start of study treatment.
- Any regional therapy to the affected extremity within 2 months prior to start of study treatment.
- Previous in vivo exposure to monoclonal antibodies for biological therapy in the 6 weeks before administration of study treatment.
- Growth factors or immunomodulatory agents within 7 days prior to the administration of study treatment.
- Subject requires or is taking corticosteroids or other immunosuppressant drugs on a long-term basis. Limited use of corticosteroids to treat or prevent acute hypersensitivity reactions is not considered an exclusion criterion.
- Participation in another interventional clinical trial during participation in this trial.
- Any conditions that in the opinion of the Investigator could hamper compliance with the study protocol.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: L19TNFα plus melphalan
Subjects will be sequentially assigned to one of 2 dose levels of L19TNFα: 325 µg or 650 µg.
All subjects will receive a single dose of L19TNFα and Melfalan (10mg/ L Limb volume).
|
Single Melphalan bolus perfused for 60 min after 30 min of L19TNFα bolus.
Intra-arterial (IA) infusion via bolus at 39˚C to 40˚C (mild hyperthermia).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety and Tolerability
Time Frame: 6 weeks
|
The safety and tolerability profile of L19TNFα/melphalan combination treatment in the ILP setting will be determined.
|
6 weeks
|
Recommended dose (RD)
Time Frame: 29 days
|
The recommended dose (RD) of L19TNFα when given in combination with melphalan in the ILP setting for subjects with limb stage III/IV melanoma will be determined.
|
29 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective response rate
Time Frame: 10 weeks
|
Objective response rate of L19TNFα plus melphalan.
|
10 weeks
|
Antitumor activity
Time Frame: 4- 6 weeks
|
Antitumor activity of L19TNFα plus melphalan (resection of residual tumor after 4- 6 weeks and histopathological response rate).
|
4- 6 weeks
|
Pharmacokinetic
Time Frame: 10 days
|
Pharmacokinetic profile of L19TNFα when given with melphalan
|
10 days
|
Human anti-fusion protein antibody
Time Frame: 6 weeks
|
Assessment of possible induction of human anti-fusion protein antibody [HAFA] formation
|
6 weeks
|
5-hydroxyindoleacetic acid
Time Frame: 10 days
|
Assessment of plasma profile of 5-hydroxyindoleacetic acid (5-HIAA), a surrogate marker of vascular damage and tumor response.
|
10 days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Franco De Cian, Prof, IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PH-L19TNFαILP-01-08
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Patients With Intransit Stage III/IV Melanoma
-
Abramson Cancer Center of the University of PennsylvaniaTerminatedClinical Stage III Nodal or Intransit Disease or Resectable Stage IV MelanomaUnited States
-
Emory UniversityGenentech, Inc.Active, not recruitingStage IV Skin Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Unresectable Melanoma | Stage III Melanoma | Stage IIIA Skin Melanoma | Cutaneous Melanoma, Stage III | Cutaneous Melanoma, Stage IVUnited States
-
Elizabeth Buchbinder, MDGenentech, Inc.RecruitingStage IV Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Unresectable Stage III Cutaneous Melanoma | Unresectable Stage IV Cutaneous MelanomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingMetastatic Melanoma | Unresectable Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage III Cutaneous Melanoma AJCC v8 | Clinical Stage IV Cutaneous Melanoma AJCC v8 | Pathologic Stage IV Cutaneous Melanoma AJCC v8United States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingClinical Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Pathologic Stage IIID Cutaneous Melanoma AJCC v8 | Pathologic Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIA Cutaneous Melanoma... and other conditionsUnited States
-
MelanomaPRO, RussiaRecruitingMelanoma | Melanoma (Skin) | Melanoma Stage IV | Melanoma Stage III | Melanoma, Stage II | Melanoma, Uveal | Melanoma in Situ | Melanoma, OcularRussian Federation
-
University of Colorado, DenverMerck Sharp & Dohme LLCActive, not recruitingStage IV Melanoma | Advanced Melanoma | Stage III MelanomaUnited States
-
Dana-Farber Cancer InstitutePartner Therapeutics (PTx)WithdrawnMetastatic Melanoma | Unresectable Melanoma | Stage IV Melanoma | Stage III MelanomaUnited States
-
NewLink Genetics CorporationCompletedMetastatic Melanoma | Stage IV Melanoma | Stage III MelanomaUnited States
-
Scancell LtdRecruitingMelanoma (Skin) | Malignant Melanoma | Melanoma Stage IV | Melanoma Stage IIIUnited Kingdom
Clinical Trials on Isolated inferior limb perfusion
-
Vastra Gotaland RegionRecruiting
-
University of Santiago de CompostelaCompleted
-
Vastra Gotaland RegionCompleted
-
Vastra Gotaland RegionRecruitingMelanoma | In-Transit MetastasisSweden, Netherlands
-
Oregon Health and Science UniversityUnknownPeripheral Artery DiseaseUnited States
-
New Approaches to Brain Tumor Therapy ConsortiumNational Cancer Institute (NCI)CompletedBrain and Central Nervous System TumorsUnited States
-
Gustave Roussy, Cancer Campus, Grand ParisCompleted
-
Albert Einstein College of MedicineNational Cancer Institute (NCI)WithdrawnRecurrent Melanoma | Stage IV Melanoma | Recurrent Adult Soft Tissue Sarcoma | Stage III Adult Soft Tissue Sarcoma | Stage IV Adult Soft Tissue Sarcoma | Squamous Cell Carcinoma of the Skin | Recurrent Skin Cancer | Stage IIIB Melanoma | Stage IIIC Melanoma | Basal Cell Carcinoma of the Skin | Eccrine Carcinoma...United States
-
European Organisation for Research and Treatment...TerminatedMetastatic Cancer | Intraocular MelanomaSwitzerland, Italy, United Kingdom, Poland
-
National Cancer Institute (NCI)Completed